CLS is committed to providing the media with timely and accurate information related to California’s life sciences ecosystem. CLS welcomes all media inquiries from news organizations and reporters. Members of the media interested in speaking with CLS opinion leaders on issues of public policy, life sciences innovation, or issues related to the life sciences ecosystem in California, please contact our communication department.

Media Contact: [email protected]

Biotech Takes On Racial And Social Equity. Are The Efforts Sustainable?

Mar 23, 2021

From holding Covid-19 vaccination events in San Francisco’s Tenderloin neighborhood to building programs that target longstanding inequities, the Bay Area biotech industry is stepping into high-profile social issues like never before.

Read More

CLSA/CLSI Announce Initiation Of Mentoring, Coaching And Professional Development Programs To Help Address Gaps In Representation And Inequity In The California Life Sciences Industry

Mar 18, 2021

The California Life Sciences Association (CLSA)/California Life Sciences Institute (CLSI) announced the creation of the Racial & Social Equity (RSE) Initiative, part of a multi-year program, funded by CLSA/CLSI member companies, with the goal of helping close the gaps in inequity and create a more diverse industry. The RSE Initiative has already surpassed its initial fundraising budget of $1M, with a goal of sustaining 3-year commitments of $1M annually.

Read More

CLSA Welcomes New Board Members And Kicks Off Robust 2021

Mar 8, 2021

California Life Sciences Association (CLSA), the trade association representing California’s life sciences sector announces the election of three new members to its Board of Directors and the transition of two leadership positions.

Read More

CLSA Applauds The Release The Medicare Coverage Of Innovative Technology (MCIT) Final Rule

Jan 28, 2021

Earlier this month, the Centers for Medicare and Medicaid Services (CMS) released the final “Medicare Coverage of Innovative Technology (MCIT) and Definition of ‘Reasonable and Necessary” rule (42 CFR Part 405).  The rule, if implemented as planned in March of this year, creates a pathway for automatic CMS coverage – for 4 years – of medical devices that receive Food and Drug Administration (FDA) breakthrough technologies program designation and subsequent market authorization through their Expedited Review Approval Process.

Read More

California Unveils New Approach To Vaccine Allocation And Distribution

Jan 27, 2021

On Tuesday, January 26, Governor Newsom revised the vaccine rollout plan to help streamline allocation and distribution. Vaccine distribution will now be led by the Government Operations Agency along with CA Health and Human Services and CA Department of Public Health.

Read More

CLSA And BIO Hosted A Briefing “The Transformative Potential Of Gene Therapies”

Jan 27, 2021

On Tuesday, January 26th CLSA and BIO hosted a briefing titled, “The Transformative Potential of Gene Therapies” in partnership with the California Select Committee on Biotechnology and the California Rare Disease Caucus. This briefing was moderated by Assemblymember Kevin Mullin and was attended by legislators, legislative staff and members of the rare disease community who are interested in learning more about gene therapies.

Read More